Literature DB >> 12625930

The natural history of Sudanese post-kala-azar dermal leishmaniasis: clinical, immunological and prognostic features.

A M Musa1, E A G Khalil, M A Raheem, E E Zijlstra, M E Ibrahim, I M Elhassan, M M Mukhtar, A M El Hassan.   

Abstract

In an exploration of the natural history of post-kala-azar dermal leishmaniasis (PKDL), 134 residents of Sudan who had recently been diagnosed as cases of the disease were investigated. In each case, diagnosis had been based on clinical criteria, the temporal relationship between the rash and the treatment of visceral leishmaniasis (VL), positive results in direct agglutination tests (DAT) and/or leishmanin skin tests (LST), and the exclusion of other skin conditions. The mean (S.D.) age of the subjects was 6.4 (3.0) years. Although PKDL appeared commonest among those aged 4-8 years (P < 0.05), it was most severe in children aged <or= 3 years. Males and females were equally affected. The rash developed 0.5-13 months following the apparently successful treatment of VL, a relatively rapid onset being associated with severe disease (P = 0.01). The distribution of the rash on the body often reflected the clothing habits of the case, being most frequent on skin that was regularly exposed to the sun. Spontaneous healing of the lesions occurred within 12 months in the majority of cases, the PKDL lasting for a mean (S.D.) of 9.7 (4.7) months. Persistence of lesions beyond 1 year was significantly associated with the combination of a high titre in the DAT and a negative result in the LST (P < 0.05). In conclusion, spontaneous healing is commonly seen in Sudanese patients with PKDL. Persistence of the lesions is frequently associated with non-reactivity in the LST and high levels of anti-leishmanial antibodies.

Entities:  

Mesh:

Year:  2002        PMID: 12625930     DOI: 10.1179/000349802125002211

Source DB:  PubMed          Journal:  Ann Trop Med Parasitol        ISSN: 0003-4983


  25 in total

1.  Dichotomy of protective cellular immune responses to human visceral leishmaniasis.

Authors:  E A G Khalil; N B Ayed; A M Musa; M E Ibrahim; M M Mukhtar; E E Zijlstra; I M Elhassan; P G Smith; P M Kieny; H W Ghalib; F Zicker; F Modabber; A M Elhassan
Journal:  Clin Exp Immunol       Date:  2005-05       Impact factor: 4.330

Review 2.  Recent Development of Visceral Leishmaniasis Treatments: Successes, Pitfalls, and Perspectives.

Authors:  Fabiana Alves; Graeme Bilbe; Séverine Blesson; Vishal Goyal; Séverine Monnerat; Charles Mowbray; Gina Muthoni Ouattara; Bernard Pécoul; Suman Rijal; Joelle Rode; Alexandra Solomos; Nathalie Strub-Wourgaft; Monique Wasunna; Susan Wells; Eduard E Zijlstra; Byron Arana; Jorge Alvar
Journal:  Clin Microbiol Rev       Date:  2018-08-29       Impact factor: 26.132

3.  Significance of persistence of antibodies against Leishmania infantum in Sicilian patients affected by acute visceral leishmaniasis.

Authors:  Pasquale Mansueto; Ilenia Pepe; Aurelio Seidita; Francesca Scozzari; Giustina Vitale; Francesco Arcoleo; Inglese Elvira; Enrico Cillari; Giovam Battista Rini; Nicola Napoli; Salvatore Di Rosa; Serafino Mansueto; Gaetana Di Fede
Journal:  Clin Exp Med       Date:  2011-06-29       Impact factor: 3.984

4.  Post-kala-azar dermal leishmaniasis in Nepal: a retrospective cohort study (2000-2010).

Authors:  Surendra Uranw; Bart Ostyn; Arpana Rijal; Saru Devkota; Basudha Khanal; Joris Menten; Marleen Boelaert; Suman Rijal
Journal:  PLoS Negl Trop Dis       Date:  2011-12-20

5.  Interleukin 10 gene polymorphisms and development of post kala-azar dermal leishmaniasis in a selected sudanese population.

Authors:  S Farouk; M A Salih; A M Musa; J M Blackwell; E N Miller; E A Khalil; A M Elhassan; M E Ibrahim; H S Mohamed
Journal:  Public Health Genomics       Date:  2009-12-29       Impact factor: 2.000

6.  Safety and immunogenicity of ChAd63-KH vaccine in post-kala-azar dermal leishmaniasis patients in Sudan.

Authors:  Brima M Younis; Mohamed Osman; Eltahir A G Khalil; Francesco Santoro; Simone Furini; Rebecca Wiggins; Ada Keding; Monica Carraro; Anas E A Musa; Mujahid A A Abdarahaman; Laura Mandefield; Martin Bland; Toni Aebischer; Rhian Gabe; Alison M Layton; Charles J N Lacey; Paul M Kaye; Ahmed M Musa
Journal:  Mol Ther       Date:  2021-03-27       Impact factor: 11.454

7.  Post-Kala-Azar Dermal Leishmaniasis: A Paradigm of Paradoxical Immune Reconstitution Syndrome in Non-HIV/AIDS Patients.

Authors:  Eltahir Awad Gasim Khalil; Selma Abdelmoneim Khidir; Ahmed Mudawi Musa; Brema Younis Musa; Mona Elfaki Eltahir Elfaki; Abdelgadir Mohamed Yousif Elkadaru; Edward Zijlstra; Ahmed Mohamed El-Hassan
Journal:  J Trop Med       Date:  2013-03-24

8.  Treatment-based strategy for the management of post-kala-azar dermal leishmaniasis patients in the Sudan.

Authors:  A M Musa; E A G Khalil; B M Younis; M E E Elfaki; M Y Elamin; A O A Adam; H A A Mohamed; M M M Dafalla; A A Abuzaid; A M El-Hassan
Journal:  J Trop Med       Date:  2013-04-15

9.  Misdiagnosis and mistreatment of post-kala-azar dermal leishmaniasis.

Authors:  Ahmed Mohamed El Hassan; Eltahir Awad Gasim Khalil; Waleed Mohamed Elamin; Lamyaa Ahmed Mohamed El Hassan; Mogtaba Elsaman Ahmed; Ahmed Mudawi Musa
Journal:  Case Rep Med       Date:  2013-02-21

10.  Consultation meeting on the development of therapeutic vaccines for post kala azar dermal leishmaniasis.

Authors:  Hashim Ghalib; Farrokh Modabber
Journal:  Kinetoplastid Biol Dis       Date:  2007-08-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.